TacticScaleWhat Ligand Pharmaceuticals Does & How It Makes Money (LGND)
Updated October 2026 · reflects Ligand Pharmaceuticals's latest reported financials
Biopharma royalty company licensing drug technologies and assets to partners. Ligand licenses its drug assets and technologies, such as the Captisol formulation technology, to partner companies that develop and sell the products.
How Ligand Pharmaceuticals makes money
Ligand licenses its drug assets and technologies, such as the Captisol formulation technology, to partner companies that develop and sell the products. Its income is implied to come mainly from licensing payments and royalties on partner sales rather than from selling drugs itself.
What Ligand Pharmaceuticals does
Ligand Pharmaceuticals, founded in 1987 and based in Jupiter, Florida, develops biopharmaceutical assets and licenses them to partners worldwide. Its portfolio covers many therapeutic areas. It includes infectious disease products such as NOXAFIL, VEKLURY, CAPVAXIVE and VAXNEUVANCE. Cancer treatments include KYPROLIS, EVOMELA, QARZIBA and RYLAZE. Other products include FILSPARI for IgA nephropathy, TZIELD for delaying type 1 diabetes, and Nexterone, a Captisol-enabled form of amiodarone. Beyond marketed products, Ligand has interests in a wide partner pipeline. It spans oncology (e.g., Ciforadenant, Lasofoxifene), respiratory disease (Ensifentrine), liver disease (VK2809), ophthalmology (Reproxalap) and rare diseases. This spread across many partnered products gives investors diversified exposure to biopharma rather than reliance on a single drug.
Products & services
- KYPROLIS
- FILSPARI
- VEKLURY
- CAPVAXIVE
- Captisol (e.g., Nexterone)
- TZIELD
What is Ligand Pharmaceuticals worth?
On an owner-earnings DCF, Ligand Pharmaceuticals's most-likely value is about $252 versus a recent price near $302 (16% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$69) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Gilead Sciences (GILD) · Lantheus (LNTH) · Regeneron Pharmaceuticals (REGN)